One-and-Done or Dose-and-Repeat? Gene Editing Faces RNA Competition

The gene editing field is advancing quickly, yet a critical question is emerging: when does a permanent genomic edit outperform repeat-dose RNA therapies? The answer has major implications for investors, developers, and clinicians alike.

Gene editing’s appeal lies in its "one-and-done" promise of a single treatment that permanently addresses genetic defects. However, RNA-based approaches, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), are beginning to narrow that gap. These therapies use RNA, the molecule that helps carry genetic instructions in cells, to change how genes behave without permanently altering DNA. Advances in these therapies have improved effectiveness and extended dosing intervals, making them an attractive option for patients and providers seeking a safer, more flexible alternative to permanent DNA editing.

RNA therapies also benefit from a well-established safety profile and can be adjusted or discontinued if issues arise. By comparison, gene editing continues to face challenges, including off-target effects and other unintended genetic changes. While permanent edits may offer long-term benefits, any mistakes can persist for the life of the cell.

This competition between RNA and gene editing is particularly intense in simple gene knockouts, which involve deliberately inactivating or deleting a specific gene to eliminate its expression. In many cases, RNA therapies can achieve similar therapeutic outcomes without the risk of permanent DNA modifications.

Still, gene editing maintains important advantages, however, in areas where RNA therapies have limitations. These include gene correction, which repairs the underlying mutation; gene insertion, which enables long-term expression of functional genes; and gene upregulation, which increases gene activity. These applications address biological challenges that RNA therapies are generally unable to replicate.

For investors, the key consideration is differentiation. Gene editing may be most compelling when it provides benefits that RNA therapies cannot. In settings where both approaches can deliver similar outcomes, the safety and flexibility of RNA-based treatments may make them the preferred option.

The "one-and-done" promise of gene editing remains compelling, but the science must continue to prove its value in areas where RNA therapies cannot compete. For more information on related investment opportunities and insights, read DECODER – CRISPR and Sharper: Gene Editing Technologies Shaping the Next Generation of Therapeutics, published on April 1, 2026, by Myles Minter, Ph.D., partner, and equity research analyst for the healthcare sector.